Previous close | 1.4300 |
Open | 1.4200 |
Bid | 1.0800 x 200 |
Ask | 1.9200 x 200 |
Day's range | 1.4200 - 1.5100 |
52-week range | 1.4200 - 2.3600 |
Volume | |
Avg. volume | 10,049 |
Market cap | 21.407M |
Beta (5Y monthly) | 0.17 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced the release of a Special Report evaluating the growing amount of current data supporting the use of its Caldolor® product (intravenous ibuprofen, or IVIB) as a standard of care for the treatment of pain and fever in adults, children and infants.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $40 million in 2023 and provided $6 million in cash generated from operations.